X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.760
+0.060 (1.62%)
At close: Mar 6, 2026, 4:00 PM EST
3.750
-0.010 (-0.27%)
After-hours: Mar 6, 2026, 7:12 PM EST
X4 Pharmaceuticals Employees
X4 Pharmaceuticals had 143 employees as of December 31, 2024. The number of employees increased by 50 or 53.76% compared to the previous year.
Employees
143
Change (1Y)
50
Growth (1Y)
53.76%
Revenue / Employee
$237,615
Profits / Employee
-$665,000
Market Cap
328.76M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 172 |
| Cabaletta Bio | 151 |
| Adlai Nortye | 123 |
| Foghorn Therapeutics | 112 |
| Rezolute | 75 |
| Immuneering | 54 |
| Protara Therapeutics | 33 |
| Avalo Therapeutics | 23 |
XFOR News
- 3 days ago - X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference - GlobeNewsWire
- 4 days ago - X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval - Seeking Alpha
- 5 days ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome - GlobeNewsWire
- 19 days ago - X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 4 weeks ago - X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 3 months ago - X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia - Seeking Alpha
- 4 months ago - X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference - GlobeNewsWire